CD1C and melanoma: Mechanistically, in a Stage III/IV melanoma population undergoing bleomycin-based ECT, Gerlini et al. highlighted the increase in CD1c+ dermal dendritic cells (dDCs) during treatment; day 0 (5.63%); day 7 (8.34%); day 14 (16.11%); p < 0.05 and p < 0.001 [51].